Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 9/4/2024 | $9.00 | Buy | H.C. Wainwright |
| 5/6/2024 | $8.00 | Buy | Craig Hallum |
| 10/14/2021 | $10.00 | Buy | B. Riley Securities |
SC 13G/A - Eton Pharmaceuticals, Inc. (0001710340) (Subject)
SC 13D/A - Eton Pharmaceuticals, Inc. (0001710340) (Subject)
SC 13G/A - Eton Pharmaceuticals, Inc. (0001710340) (Subject)
4 - Eton Pharmaceuticals, Inc. (0001710340) (Issuer)
4 - Eton Pharmaceuticals, Inc. (0001710340) (Issuer)
4 - Eton Pharmaceuticals, Inc. (0001710340) (Issuer)
Reported total revenue of $10.3 million and GAAP Net Income of $0.6 million, or $0.02 per diluted shareEntered into an asset purchase agreement to acquire Increlex® (mecasermin injection)Q3 2024 product sales increased 40% over Q3 2023, representing 15th straight quarter of sequential product sales growthProduced positive quarterly GAAP net income from product sales for first time in company historyGenerated cash from operations of $2.9 million in Q3 2024Granted additional patent for ET-400Management to hold conference call today at 4:30pm ET DEER PARK, Ill., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc ("Eton" or "the Company") (NASDAQ:ETON), an innovative pharmaceutical c
- Product has patent protection through 2043 -- Prescription Drug User Fee Act (PDUFA) target action date of February 28, 2025 - DEER PARK, Ill., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc ("Eton" or the "Company") (NASDAQ:ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that the United States Patent and Trademark Office (USPTO) has granted the Company U.S. Patent Application No. 18/443,889, now U.S. Patent No. 12,133,914, for ET-400, a proprietary patented formulation of liquid hydrocortisone. The patent, which expires in 2043, covers a method of using hydrocortisone oral liquid formulat
DEER PARK, Ill., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. ("Eton" or the "Company") (NASDAQ:ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it will report third quarter 2024 financial results on Tuesday, November 12, 2024. Management will host a conference call and live audio webcast to discuss the results at 4:30 p.m. ET (3:30 p.m. CT). Dial in (Audio Only) Toll-free: 888-596-4144 Non-toll free: 646-968-2525 Access Code: 1144771 Webcast: Click Here In addition to taking live questions from participants on the conference call, management will be answering emailed questions fr
Reported total revenue of $10.3 million and GAAP Net Income of $0.6 million, or $0.02 per diluted shareEntered into an asset purchase agreement to acquire Increlex® (mecasermin injection)Q3 2024 product sales increased 40% over Q3 2023, representing 15th straight quarter of sequential product sales growthProduced positive quarterly GAAP net income from product sales for first time in company historyGenerated cash from operations of $2.9 million in Q3 2024Granted additional patent for ET-400Management to hold conference call today at 4:30pm ET DEER PARK, Ill., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc ("Eton" or "the Company") (NASDAQ:ETON), an innovative pharmaceutical c
DEER PARK, Ill., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. ("Eton" or the "Company") (NASDAQ:ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it will report third quarter 2024 financial results on Tuesday, November 12, 2024. Management will host a conference call and live audio webcast to discuss the results at 4:30 p.m. ET (3:30 p.m. CT). Dial in (Audio Only) Toll-free: 888-596-4144 Non-toll free: 646-968-2525 Access Code: 1144771 Webcast: Click Here In addition to taking live questions from participants on the conference call, management will be answering emailed questions fr
Company Announces Q3 Earnings and Conference Call Dates DALLAS, TX / ACCESSWIRE / October 17, 2024 / SWK Holdings Corporation (NASDAQ:SWKH) ("SWK" or the "Company"), a life science-focused specialty finance company catering to small- and mid-sized commercial-stage companies, provided today a portfolio update and announced the anticipated date of the third quarter earnings and conference call schedule.The Company intends to issue their third quarter financials after market close on November 14, 2024, and will host a conference call at 9:00 a.m. Central Time on November 15, 2024, to discuss the company's financial results for the quarter. Call details will be available in the quarterly results
4 - Eton Pharmaceuticals, Inc. (0001710340) (Issuer)
4 - Eton Pharmaceuticals, Inc. (0001710340) (Issuer)
4 - Eton Pharmaceuticals, Inc. (0001710340) (Issuer)
DEER PARK, Ill., April 11, 2022 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (NASDAQ:ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced the appointment of James Gruber as Chief Financial Officer, effective immediately. He succeeds Wilson Troutman, who is retiring. Mr. Troutman will remain with the company through the end of May to ensure a smooth transition. "We are pleased to welcome James to the Eton team. He brings a wealth of experience managing the finance and accounting activities for some of the most successful companies in the industry. We look forward to benefiting from his financial expertise as we
LONDON, Nov. 18, 2021 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV:DMT) (OTCQB:DMTTF) (the "Company" or "Small Pharma"), a neuropharmaceutical company focused on psychedelic-assisted therapies, announces that Mr. Paul Maier has been appointed as a non-executive independent director of the board of directors of the Company (the "Board"). He will hold office as an independent director until the next annual meeting of shareholders, or until his successor has been elected or appointed. Mr. Maier has also been appointed as a member of the Audit Committee and Corporate Governance and Nominating Committee and Chair of the Compensation Committee. Mr. Maier joins Small Pharma with over 30 years' ex
DEER PARK, Ill., March 17, 2021 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it has appointed Jenn Adams to its board of directors effective March 17, 2021. Ms. Adams brings extensive commercial, operational, and leadership experience in the pharmaceutical industry. “We are pleased to have Jenn join our board. Her experience growing pharmaceutical companies and leading sales organizations will be valuable to Eton as we continue to launch products and grow our commercial organization,” said Sean Brynjelsen, CEO of Eton Pharmaceuticals. Ms. Adam
10-Q - Eton Pharmaceuticals, Inc. (0001710340) (Filer)
8-K - Eton Pharmaceuticals, Inc. (0001710340) (Filer)
8-K - Eton Pharmaceuticals, Inc. (0001710340) (Filer)
H.C. Wainwright resumed coverage of Eton Pharmaceuticals with a rating of Buy and set a new price target of $9.00
Craig Hallum initiated coverage of Eton Pharmaceuticals with a rating of Buy and set a new price target of $8.00
B. Riley Securities resumed coverage of Eton Pharmaceuticals with a rating of Buy and set a new price target of $10.00
- Prescription Drug User Fee Act (PDUFA) target action date is February 28, 2025 - - Product has patent protection through 2043 -
Eton Pharmaceuticals (NASDAQ:ETON) reported quarterly losses of $(0.03) per share which beat the analyst consensus estimate of $(0.07) by 57.14 percent. This is a 70 percent increase over losses of $(0.10) per share from the same period last year. The company reported quarterly sales of $7.966 million which missed the analyst consensus estimate of $8.000 million by 0.43 percent. This is a 50.19 percent increase over sales of $5.304 million the same period last year.